col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: Biomedicine & Pharmacotherapy
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―29 Interleukin-17A (IL-17A): a silent amplifier of COVID-19 Francesco Maione, Gian Marco Casillo, Federica Raucci, Cristian Salvatore, Giovanna Ambrosini, Luisa Costa, et al. (+3)
2 [GO] 2021―Jul―28 In silico drug repurposing in COVID-19: a network-based analysis Pasquale Sibilio, Simone Bini, Giulia Fiscon, Marialuisa Sponziello, Federica Conte, Valeria Pecce, et al. (+6)
3 [GO] 2021―Jul―28 Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection Annoor Awadasseid, Qiang Yin, Yanling Wu, Wen Zhang
4 [GO] 2021―Jul―27 Kidney injury in COVID-19 patients, drug development and their renal complications: Review study Zeynab Mohamadi Yarijani, Houshang Najafi
5 [GO] 2021―Jul―27 A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status Apu Chowdhury, Muhammad Sajid, Nabila Jahan, Temitope Isaac Adelusi, Pulak Maitra, Guolian Yin, et al. (+3)
6 [GO] 2021―Jul―23 Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2 Javier T. Granados-Riveron, Guillermo Aquino-Jarquin
7 [GO] 2021―Jul―14 Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19? Ilaria Farella, Raffaella Panza, Manuela Capozza, Nicola Laforgia
8 [GO] 2021―Jun―10 Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options Shetty Ravi Dyavar, Rahul Singh, Rohini Emani, Ganesh P. Pawar, Vinod D. Chaudhari, Anthony T. Podany, et al. (+3)
9 [GO] 2021―Jun―05 Identification of oligopeptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non structural protein 8 (NSP8) and their similarities with type 1 angiotensin II receptor key sites Ammar Achour
10 [GO] 2021―May―28 Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 Serena Patel, Meenu Wadhwa
11 [GO] 2021―May―27 CRISPR is a useful biological tool for detecting nucleic acid of SARS-CoV-2 in human clinical samples Md. Rashidur Rahman, Md. Amjad Hossain, Md. Mozibullah, Fateh Al Mujib, Afrina Afrose, Md. Shahed-Al-Mahmud, Md. Aminul Islam Apu
12 [GO] 2021―May―24 Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease Osvaldo Yañez, Manuel Isaías Osorio, Carlos Areche, Alejandro Vasquez-Espinal, Jessica Bravo, Angélica Sandoval-Aldana, et al. (+6)
13 [GO] 2021―May―18 Main Protease Inhibitors and Drug Surface Hotspots for the Treatment of COVID-19: A Drug Repurposing and Molecular Docking Approach Mahmudul Hasan, Md. Sorwer Alam Parvez, Kazi Faizul Azim, Md. Abdus Shukur Imran, Topu Raihan, Airin Gulshan, et al. (+4)
14 [GO] 2021―May―15 Corrigendum to: “Novel and emerging mutations of SARS-CoV-2: Biomedical implications” [Biomed. Pharmacother. 139 (2021) 111599] Elmira Mohammadi, Fatemeh Shafiee, Kiana Shahzamani, Mohammad Mehdi Ranjbar, Abbas Alibakhshi, Shahrzad Ahangarzadeh, et al. (+5)
15 [GO] 2021―May―06 COVID-19 and Metabolic Comorbidities: An Update on Emerging Evidences for Optimal Therapies Shuang Hua, Yong Yang, Danqi Zou, Jufei Li, Kaixuan Yan, Ying Xu, et al. (+3)
16 [GO] 2021―Apr―27 Disease-drug and drug-drug interaction in COVID-19: risk and assessment Devendra Kumar, Neerja Trivedi
17 [GO] 2021―Apr―23 Novel and emerging mutations of SARS-CoV-2: Biomedical implications Elmira Mohammadi, Fatemeh Shafiee, Kiana Shahzamani, Mohammad Mehdi Ranjbar, Abbas Alibakhshi, Shahrzad Ahangarzadeh, et al. (+5)
18 [GO] 2021―Apr―21 Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy Mina T. Kelleni
19 [GO] 2021―Apr―08 Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment Jing Qian, Hangdi Xu, Dongqing Lv, Wei Liu, Enguo Chen, Yong Zhou, et al. (+3)
20 [GO] 2021―Apr―06 Angiotensin II: A possible target for therapeutic intervention in COVID-19 Mohammad Rafi Khezri, Keyvan Yousefi, Morteza Ghasemnejad-Berenji
21 [GO] 2021―Apr―06 WILL CURCUMIN NANOSYSTEMS BE THE NEXT PROMISING ANTIVIRAL ALTERNATIVES IN COVID-19 TREATMENT TRIALS? Douglas Dourado, Danielle T. Freire, Daniel T. Pereira, Lucas Amaral-Machado, Éverton N. Alencar, André Luis Branco de Barros, E. Sócrates T. Egito
22 [GO] 2021―Apr―01 Identification of FDA Approved Drugs Against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) and 3-chymotrypsin-like Protease (3CLpro), Drug Repurposing Approach Zahra Molavi, Sara Razi, Seyed Amir Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, et al. (+10)
23 [GO] 2021―Mar―20 Efficacy of Brazilian Green Propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial Marcelo Augusto Duarte Silveira, David De Jong, Andresa Aparecida Berretta, Erica Batista dos Santos Galvão, Juliana Caldas Ribeiro, Thiago Cerqueira-Silva, et al. (+19)
24 [GO] 2021―Mar―18 Potential Therapeutic Agents to COVID-19: An Update Review on Antiviral Therapy, Immunotherapy, and Cell Therapy Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, Jalal Heshmatnia, Reza Falak, Reza Zolfaghari Emameh
25 [GO] 2021―Mar―18 Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Oliver Bushljetikj, Lucian Calmac, Tom Johnson, et al. (+61)
26 [GO] 2021―Mar―06 Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2 Kenneth S. Plante, Varun Dwivedi, Jessica A. Plante, Diana Fernandez, Divya Mirchandani, Nathen Bopp, et al. (+11)
27 [GO] 2021―Feb―26 Flavonoids against the SARS-CoV-2 induced inflammatory storm Alena Liskova, Marek Samec, Lenka Koklesova, Samson M. Samuel, Kevin Zhai, Raghad Khalid AL-Ishaq, et al. (+17)
28 [GO] 2021―Feb―25 Fluoxetine as an Anti-Inflammatory Therapy in SARS-CoV-2 Infection Justin Fortune Creeden, Ali Sajid Imami, Hunter M. Eby, Cassidy Gillman, Kathryn N. Becker, Jim Reigle, et al. (+5)
29 [GO] 2021―Feb―15 Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection Sheila Maestro, Karol M. Córdoba, Cristina Olague, Josepmaria Argemi, Matías A. Ávila, Gloria González-Aseguinolaza, et al. (+2)
30 [GO] 2021―Feb―06 Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity Maryam Eskandari Mehrabadi, Roohullah Hemmati, Amin Tashakor, Ahmad Homaei, Masoumeh Yousefzadeh, Karim Hemati, Saman Hosseinkhani
31 [GO] 2021―Feb―05 Research Progress of Traditional Chinese Medicine Against COVID-19 Wei Ren, Pan Liang, Yue Ma, Qin Sun, Qingrong Pu, Li Dong, et al. (+5)
32 [GO] 2021―Feb―05 An update review of emerging small-molecule therapeutic options for COVID-19 Dengke Tian, Yuzhi Liu, Chengyuan Liang, Liang Xin, Xiaolin Xie, Dezhu Zhang, et al. (+5)
33 [GO] 2021―Feb―05 Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies Akalesh Kumar Verma, Vikas Kumar, Sweta Singh, Bhabesh Ch. Goswami, Ihosvany Camps, Aishwarya Sekar, et al. (+2)
34 [GO] 2021―Feb―03 SARS-CoV-2: From the pathogenesis to potential anti-viral treatments Peyman Kheirandish Zarandi, Mohammad Reza Zinatizadeh, Maryam Zinatizadeh, Mohammad Hadi Yousefi, Nima Rezaei
35 [GO] 2021―Jan―28 Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review Saniya Mahendiratta, Seema Bansal, Phulen Sarma, Harish Kumar, Gajendra Choudhary, Subodh Kumar, et al. (+3)
36 [GO] 2021―Jan―28 Targets and strategies for vaccine development against SARS-CoV-2 Jonaid Ahmad Malik, Almas Hanif Mulla, Tahmeena Farooqi, Faheem Hyder Pottoo, Sirajudheen Anwar, Kannan R.R. Rengasamy
37 [GO] 2021―Jan―28 Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang
38 [GO] 2021―Jan―15 The Direct Evidence and Mechanism of Traditional Chinese Medicine Treatment of COVID-19 Xuedong An, YueHong Zhang, Liyun Duan, De Jin, Shenghui Zhao, RongRong Zhou, et al. (+3)
39 [GO] 2021―Jan―14 The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators Hosam M. Habib, Sahar Ibrahim, Aamnah Zaim, Wissam H. Ibrahim
40 [GO] 2021―Jan―14 Human endeavor for anti-SARS-CoV-2 pharmacotherapy: a major strategy to fight the pandemic Ruixuan Wang, Preyesh Stephen, Yi Tao, Wenfa Zhang, Sheng-Xiang Lin
41 [GO] 2021―Jan―13 Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines Wagner Gouvêa dos Santos
42 [GO] 2021―Jan―08 COVID-19 and inflammatory bowel disease: a pathophysiological assessment Chunxiu Yang, Shu-Yuan Xiao
43 [GO] 2021―Jan―08 Multifunctional Angiotensin Converting Enzyme 2, the SARS-CoV-2 Entry Receptor and Critical Appraisal of its Role in Acute Lung Injury Murat Oz, Dietrich Ernst Lorke
44 [GO] 2021―Jan―01 The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment Esmé Jansen van Vuren, Stephan F. Steyn, Christiaan B. Brink, Marisa Möller, Francois P. Viljoen, Brian H. Harvey
45 [GO] 2020―Dec―17 4-Aminoquinoline Compounds from the Spanish Flu to COVID-19 Roberto Barbosa Bazotte, Sandro Massao Hirabara, Tamires Afonso Duarte Serdan, Raquel Bragante Gritte, Talita Souza-Siqueira, Renata Gorjao, et al. (+5)
46 [GO] 2020―Dec―17 Could natural products modulate early inflammatory responses, preventing Acute Respiratory Distress Syndrome in COVID-19-confirmed patients? Lucas Amaral-Machado, Wógenes N. Oliveira, Victor M. Rodrigues, Nathan A. Albuquerque, Éverton N. Alencar, Eryvaldo S.T. Egito
47 [GO] 2020―Nov―28 Potential Effects of SARS-CoV-2 on the Gastrointestinal Tract and Liver Han-Yu Lei, Ying-He Ding, Kai Nie, Yin-Miao Dong, Jia-Hao Xu, Meng-Ling Yang, et al. (+6)
48 [GO] 2020―Nov―20 A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: a bedside-to-bench study Keng-Chang Tsai, Yi-Chia Huang, Chia-Ching Liaw, Chia-I Tsai, Chun-Tang Chiou, Chien-Jung Lin, et al. (+13)
49 [GO] 2020―Nov―17 Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection Xiao-huan Liu, Xiao Zhang, Zhen-hua Lu, You Shuang Zhu, Tao Wang
50 [GO] 2020―Nov―11 Prevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine Bianza Moise Bakadia, Feng He, Tiatou Souho, Lallepak Lamboni, Muhammad Wajid Ullah, Biaou Ode Boni, et al. (+3)
51 [GO] 2020―Nov―11 SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role Ahmad Ud Din, Maryam Mazhar, Muhammad Wasim, Waqar Ahmad, Asma Bibi, Adil Hassan, et al. (+9)
52 [GO] 2020―Nov―05 Early use of Non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes Mina T. Kelleni
53 [GO] 2020―Oct―23 Innate and adaptive immune responses against coronavirus Arezoo Hosseini, Vida Hashemi, Navid Shomali, Faezeh Asghari, Tohid Gharibi, Morteza Akbari, et al. (+2)
54 [GO] 2020―Oct―20 Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques Alexander Kwarteng, Ebenezer Asiedu, Samuel Amoah Sakyi, Samuel Opoku Asiedu
55 [GO] 2020―Oct―19 Decoding the silent walk of COVID-19: Halting its spread using old bullets Mukesh Kumar, Jitender Madan, Rupinder Kaur Sodhi, Shashi Bala Singh, Anju Katyal
56 [GO] 2020―Oct―16 Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19 Jayanta Talukdar, Bhaskar Bhadra, Tomal Dattaroy, Vinod Nagle, Santanu Dasgupta
57 [GO] 2020―Sep―30 From the perspective of Traditional Chinese Medicine: treatment of mental disorders in COVID-19 survivors Ke Ma, Xin Wang, Shiyao Feng, Xia Xushan, Hongxiu Zhang, Abdul Rahaman, et al. (+8)
58 [GO] 2020―Sep―30 Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size Hong Zhao, Qi Zhu, Chi Zhang, Jiawen Li, Ming Wei, Yuhong Qin, et al. (+6)
59 [GO] 2020―Sep―17 CRISPR/Cas13: A potential therapeutic option of COVID-19 Melika Lotfi, Nima Rezaei
60 [GO] 2020―Sep―09 Male Predisposition to Severe COVID-19: Review of Evidence and Potential Therapeutic Prospects Desmond Omane Acheampong, Isaac Kyei Barffour, Alex Boye, Enoch Aninagyei, Stephen Ocansey, Martin Tangnaa Morna
61 [GO] 2020―Aug―28 The role of Interleukin 6 inhibitors in therapy of severe COVID-19 E. Nasonov, M. Samsonov
62 [GO] 2020―Aug―27 Can a metabolism-targeted therapeutic intervention successfully subjugate coronavirus? A scientific rational Kamran Mansouri, Mohsen Rastegari-Pouyani, Maryam Ghanbri-Movahed, Mehrnoush Safarzadeh, Sara Kiani, Zahra Ghanbari-Movahed
63 [GO] 2020―Aug―24 ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 Mengzhen Dong, Jie Zhang, Xuefeng Ma, Jie Tan, Lizhen Chen, Shousheng Liu, et al. (+2)
64 [GO] 2020―Aug―24 Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 Katya Uzunova, Elena Filipova, Velichka Pavlova, Toni Vekov
65 [GO] 2020―Aug―20 Candesartan could ameliorate the COVID-19 cytokine storm Abdel G. Elkahloun, Juan M. Saavedra
66 [GO] 2020―Aug―19 Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: advances and prospects Liu-Cheng Li, Zhi-Hui Zhang, Wen-Cheng Zhou, Jie Chen, Hua-Qian Jin, Hong-Mei Fang, et al. (+4)
67 [GO] 2020―Aug―17 Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease Andresa Aparecida Berretta, Marcelo Augusto Duarte Silveira, José Manuel Cóndor Capcha, David De Jong
68 [GO] 2020―Aug―13 SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia Wei Chen, Jie Zhang, Xijian Qin, Weixiao Wang, Miaomiao Xu, Lin-Fa Wang, et al. (+9)
69 [GO] 2020―Aug―01 Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies Arif Hussain, Anwarul Hasan, Mohammad Mahdi Nejadi Babadaei, Samir Haj Bloukh, Muhammad E.H. Chowdhury, Majid Sharifi, et al. (+2)
70 [GO] 2020―Jul―30 Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19 Ulf Norinder, Astrud Tuck, Kalle Norgren, Vesna Munic Kos
71 [GO] 2020―Jul―28 Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience Yan Hu, Tingping Wang, Zhimin Hu, Xuan Wang, Zhengbin Zhang, Li Li, Peng Peng
72 [GO] 2020―Jul―28 SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach Suresh K. Alahari, Hassan Yousefi, Arash Poursheikhani, Zahra bahmanpour, Mousa Vatanmakanian, Mohammad Taheri, Ladan Mashouri
73 [GO] 2020―Jul―17 PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open Ettore Capoluongo
74 [GO] 2020―Jul―04 Clinical Retrospective Study on the Efficacy of Qingfei Paidu Decoction Combined with Western Medicine for COVID-19 Treatment Siyi Xin, Xueqi Cheng, Bo Zhu, Xiaolong Liao, Feng Yang, Lina Song, et al. (+13)
75 [GO] 2020―Jul―04 Outbreak of COVID-19: An emerging global pandemic threat Minhua Peng
76 [GO] 2020―Jul―03 Natural History of COVID-19 and Current Knowledge on Treatment Therapeutic Options Wagner Gouvea dos Santos
77 [GO] 2020―Jun―23 When science goes viral: The research response during three months of the COVID-19 outbreak Joanna Nowakowska, Joanna Sobocińska, Mateusz Lewicki, Żaneta Lemańska, Piotr Rzymski
78 [GO] 2020―Jun―19 STRATEGIES AND PERSPECTIVES TO DEVELOP SARS-CoV-2 DETECTION METHODS AND DIAGNOSTICS Rekha Jalandra, Amit K. Yadav, Damini Verma, Nishu Dalal, Minakshi Sharma, Rajeev Singh, et al. (+2)
79 [GO] 2020―Jun―19 Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a Jie Zhao, Xiaodong Yang, Chenghua Wang, Shuai Song, Kun Cao, Taohua Wei, et al. (+5)
80 [GO] 2020―May―30 Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools Qi Kong, Yue Wu, Yu Gu, Qi Lv, Feifei Qi, Shuran Gong, Xiuping Chen
81 [GO] 2020―May―25 Protection against COVID-19 injury by Qingfei Paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming Jian Chen, Yong-kui Wang, Yuan Gao, Ling-San Hu, Jiang-wei Yang, Jian-ru Wang, et al. (+4)
82 [GO] 2020―May―14 Emerging pharmacotherapies for COVID-19 Rachana Salvi, Panini Patankar
83 [GO] 2020―May―13 Advances in the relationship between coronavirus infection and cardiovascular diseases Mengmeng Zhao, Menglong Wang, Jishou Zhang, Jing Ye, Yao Xu, Zhen Wang, et al. (+3)
84 [GO] 2020―Apr―28 New understanding of the damage of SARS-CoV-2 infection outside the respiratory system Yuhao Zhang, Xiuchao Geng, Yanli Tan, Qiang Li, Can Xu, Jianglong Xu, et al. (+5)
85 [GO] 2020―Apr―23 Occupational exposure to SARS-CoV-2 in burns treatment during the COVID-19 epidemic: Specific diagnosis and treatment protocol Zhifeng Huang, Donglin Zhuang, Bing Xiong, David Xingfei Deng, Hanhua Li, Wen Lai


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.010 sec